Treatment of Myelodysplastic Syndrome in Elderly Patients
Treatment of MDS in elderly patients must be stratified by disease risk using IPSS-R or IPSS-M scoring systems, with lower-risk disease treated primarily with supportive care and erythropoiesis-stimulating agents, while higher-risk disease requires hypomethylating agents (azacitidine) or allogeneic stem cell transplantation in fit patients under 70 years. 1, 2
Risk Stratification Framework
The foundation of MDS treatment in elderly patients begins with proper risk stratification. The IPSS-R (Revised International Prognostic Scoring System) divides patients into lower-risk (very low, low, intermediate) and higher-risk (intermediate, high, very high) categories based on peripheral cytopenias, bone marrow blast percentage, and cytogenetic characteristics 1, 3. The newer molecular IPSS-M incorporates genetic mutations for enhanced prognostication 4, 3.
Critical consideration: MDS predominantly affects elderly patients with a median age of 77 years at diagnosis, and incidence increases dramatically to 55.4 per 100,000 in those ≥80 years 1. This advanced age, combined with comorbidities and frailty, fundamentally shapes treatment decisions and tolerance 5, 6.
Lower-Risk MDS Treatment Algorithm
First-Line Therapy for Anemia
For patients WITHOUT del(5q):
- Erythropoiesis-stimulating agents (ESAs), particularly EPO alpha, are the recommended first-line treatment when serum EPO levels are <500 U/L 2
- ESAs achieve response rates of 15-40% with median response duration of 8-23 months 7
- Add G-CSF if EPO alone is insufficient 2
For patients WITH del(5q) and transfusion dependence:
- Lenalidomide is the most effective drug, achieving 60-65% response rates with median RBC transfusion independence of 2-2.5 years 2
- Initial dose: 10 mg/day for 3 weeks every 4 weeks 2
- Achieves cytogenetic response in 50-75% of patients 2
- Critical pitfall: TP53 mutations (present in ~20% of del(5q) MDS) confer resistance to lenalidomide and higher AML progression risk—these patients require intensified surveillance 2
- Grade 3-4 neutropenia/thrombocytopenia occurs in ~60% during first weeks; close monitoring with dose reduction and/or G-CSF addition is essential 2
Second-Line Therapy After ESA Failure
For MDS with ring sideroblasts (MDS-RS) or SF3B1 mutation:
- Luspatercept is recommended, achieving 63% erythroid response and 38% RBC transfusion independence 2
- This represents a Category I, Level A recommendation 2
For younger patients with hypocellular MDS:
- Antithymocyte globulin (ATG) ± cyclosporine has efficacy in specific younger cohorts 2
Alternative second-line options (not approved in Europe):
Management of Other Cytopenias
Severe thrombocytopenia:
- Thrombopoietin receptor agonists (romiplostim, eltrombopag) show some efficacy but are NOT approved for MDS 2
- Use ONLY if marrow blasts <5% 2
Severe neutropenia:
Iron Chelation Therapy
Strongly recommended for:
- All allogeneic stem cell transplant candidates, even with moderate iron overload 2
- Non-transplant candidates with major iron overload (significantly reduced cardiac T2* by MRI) 2
Consider starting when:
- Received 20-60 RBC concentrates OR
- Serum ferritin >1000-2500 U/L 2
Agent selection:
- Deferasirox (oral) is preferred for ease of use 2
- Cannot use deferasirox in renal failure 2
- Deferiprone not approved in most countries due to neutropenia risk 2
Higher-Risk MDS Treatment Algorithm
For Patients <70 Years Without Major Comorbidities
Allogeneic stem cell transplantation should be proposed to ALL higher-risk MDS patients <70 years old without major comorbidities who have a donor—this is the only curative therapy 2, 3. This is a Category I, Level A recommendation 2.
Pre-transplant cytoreduction:
- Consider reducing marrow blast count with AML-like chemotherapy or hypomethylating agents when marrow blasts ≥10%, especially for non-myeloablative conditioning 2
- AML-like chemotherapy is recommended for fit patients (generally <70 years) with favorable cytogenetics and marrow blasts ≥10%, preferably as bridge to transplant 2
For Patients Not Eligible for Transplant
Azacitidine is recommended for patients with higher-risk MDS without major comorbidities not immediately eligible for allogeneic stem cell transplantation 2. This is a Category I, Level A recommendation and has been shown to improve survival 2.
Alternative hypomethylating agents include:
- Decitabine or oral decitabine/cedazuridine (approved in US in 2020) 3
Critical limitation: Despite promising novel combinations, no combination has proven superior to single-agent azacitidine 3. Patients who fail or progress after hypomethylating agents have dismal outcomes and represent a major unmet need—these patients should be enrolled in clinical trials if possible 8.
Age-Specific Considerations
The elderly MDS population requires heightened attention to:
- End-organ function and reserve 5
- Drug-drug interactions 5
- Performance status and frailty assessment 2
- Comorbidities that predict survival and therapy tolerance 9
Important nuance: While guidelines suggest transplant for patients <70 years, age alone should not be an absolute contraindication to intensive therapy including allogeneic transplant 5. However, the increased prevalence of frailty and comorbidities in elderly patients often precludes curative approaches, making palliative therapies the mainstay for most patients ≥75 years 5.
Emerging Therapies
For elderly patients failing standard approaches, consider clinical trials with:
- Imetelstat (approved 2024 for transfusion-dependent lower-risk MDS) 3
- Novel agents targeting TGF-β pathway, HIF pathway, telomerase, inflammatory signaling, or splicing machinery 8
- For higher-risk disease: venetoclax, MCL-1 inhibitors, immunotherapies, IRAK4 inhibitors 8
The treatment paradigm prioritizes quality of life and functional maintenance in this elderly population, recognizing that median age at diagnosis is 77 years and many patients cannot tolerate intensive disease-modifying approaches 1, 9.